Summary

The global Doxycycline Post-Exposure Prophylaxis Doxy-PEP market is projected to grow from US$ 2.60 million in 2025 to US$ 10.96 million by 2032, at a CAGR of 18.8% (2026-2032), driven by critical product segments and diverse end‑use applications.
Doxycycline Post-Exposure Prophylaxis Doxy-PEP refers to the use of oral doxycycline as an event-driven post-exposure prophylactic intervention for the prevention of bacterial sexually transmitted infections, primarily syphilis, chlamydia and gonorrhea, among populations assessed to have elevated exposure risk. The standard regimen is a single 200 mg doxycycline dose taken as soon as possible after sexual exposure and within 72 hours, with no more than 200 mg taken within 24 hours. Commercial supply is primarily based on established human-use oral doxycycline formulations, particularly 100 mg tablets or capsules administered as two units per prophylactic event, as well as selected 200 mg oral products. Doxycycline Post-Exposure Prophylaxis Doxy-PEP is therefore an application-defined pharmaceutical segment built on mature doxycycline manufacturing infrastructure rather than a separate molecular drug class. This study focuses on finished oral doxycycline dosage forms supplied for Doxy-PEP use and measures consumption on a standardized 200 mg dose-equivalent basis across sexual health clinics, HIV prevention programs, outpatient care and prescription pharmacy channels.
Key Findings
Global Doxy-PEP sales volume is estimated at approximately 8.7 million doses in 2025 and 13.3 million doses in 2026
One standardized Doxy-PEP dose equals 200 mg of doxycycline
The average manufacturer-level price is estimated at approximately US$0.29 per dose in 2026
North America remains the leading commercial market, supported by earlier clinical adoption and established sexual health service networks
100 mg immediate-release tablets and capsules remain the mainstream commercial dosage forms
Market Trends
Doxycycline Post-Exposure Prophylaxis Doxy-PEP is moving from localized clinical adoption toward a more structured preventive-care model integrated with sexual health and HIV prevention services. The United States has established a relatively clear clinical pathway through CDC guidance, while the UK and EU have progressively developed national and regional frameworks. WHO issued its first global recommendation on Doxy-PEP in July 2026, supporting its use for men who have sex with men and transgender women as part of comprehensive sexual health services while emphasizing antimicrobial resistance surveillance. Product development itself is not the main source of industry change, because the market relies predominantly on mature generic doxycycline formulations. Instead, market evolution is being driven by changes in prescribing practice, identification of higher-risk populations, integration with STI screening and HIV PrEP programs, and improved access through outpatient and community-based sexual health channels.
Market Dynamics
Drivers
The principal growth driver is the formalization of Doxy-PEP within bacterial STI prevention strategies. CDC recommends discussion and prescribing of 200 mg doxycycline within 72 hours after sex for eligible MSM and transgender women with recent bacterial STI history, while WHO’s 2026 guideline provides the first global policy framework for broader implementation. Continued bacterial STI burden, particularly among populations with repeated exposure risk, supports recurring demand. Because doxycycline is already widely manufactured, inexpensive and familiar to clinicians, adoption does not require development of new manufacturing technology or dedicated production infrastructure.
Restraints
Commercial expansion is constrained by the very low unit value of generic doxycycline and by the deliberately targeted nature of current clinical recommendations. Doxy-PEP is not positioned as a population-wide intervention, and eligibility remains concentrated in selected higher-risk populations. ECDC specifically recommends individualized use rather than population-level deployment and highlights concerns regarding antimicrobial resistance, particularly in relation to gonorrhea prevention. These factors limit both the addressable population and manufacturers’ ability to achieve significant price premiums despite rapid growth in prescription volume.
Opportunities
The strongest opportunities lie in the geographic expansion of structured Doxy-PEP programs and deeper integration with HIV PrEP, routine STI screening and specialist sexual health services. Markets with established generic doxycycline supply but limited formal Doxy-PEP adoption can scale relatively rapidly once national guidance and reimbursement pathways become clearer. Additional opportunities may emerge from optimized dispensing formats, 200 mg single-dose presentations, adherence-oriented packaging and digital prescription models that simplify episodic prophylactic use. Expansion will be strongest where high-risk populations can be reached through established sexual health infrastructure and regular follow-up.
Challenges
The central long-term challenge is balancing preventive efficacy with antimicrobial stewardship. WHO and ECDC both emphasize monitoring for antimicrobial resistance and broader ecological effects of repeated antibiotic exposure. Geographic differences in prescribing policies, resistance patterns, access to sexual health services and clinician acceptance could lead to uneven commercialization. The mature generic nature of doxycycline also means that manufacturers face intense price competition, limited differentiation and low incremental margins, making market participation more dependent on scale, regulatory coverage and supply-chain efficiency than on proprietary product technology.
Industry Chain Analysis
The upstream segment comprises doxycycline active pharmaceutical ingredient production, excipients, capsule shells, tableting materials, packaging materials and pharmaceutical-grade intermediates. The supply base is concentrated among established antibiotic API and generic-drug manufacturing clusters, particularly in India, China and other major pharmaceutical manufacturing regions. Midstream participants manufacture finished oral doxycycline formulations, mainly 100 mg tablets and capsules and selected 200 mg products, under GMP-controlled oral solid dosage production systems. Doxy-PEP does not generally require dedicated manufacturing lines, allowing producers to use existing doxycycline and oral-solid production capacity.
The downstream chain includes national and regional pharmaceutical distributors, hospital and community pharmacies, sexual health clinics, HIV PrEP programs, specialist outpatient services and other prescription channels. Value creation is concentrated less in formulation innovation than in reliable low-cost manufacturing, regulatory approvals, national distribution access and continuity of supply. The relatively small volume attributable specifically to Doxy-PEP compared with total global oral-solid pharmaceutical capacity means that supply availability is not expected to be a structural constraint. Competitive economics therefore favor manufacturers with established doxycycline registrations, efficient generic manufacturing networks and broad market access.
Segment Insights
The commercial product structure is dominated by 100 mg immediate-release doxycycline tablets and capsules. These formats benefit from broad regulatory availability, mature generic competition and easy conversion into the standard 200 mg prophylactic dose through administration of two units. They are therefore expected to account for the majority of Doxy-PEP volume. Direct 200 mg formulations, including selected delayed-release products, represent a smaller segment but offer convenience by reducing the number of units required per prophylactic event.
From a commercial perspective, standardized low-cost generic formulations are expected to remain dominant because Doxy-PEP prescribing guidance generally permits doxycycline across conventional formulations rather than requiring a specialized branded product. This limits opportunities for substantial formulation-based premium pricing. Product differentiation is more likely to emerge through packaging configuration, patient convenience, pharmacy dispensing efficiency and regional regulatory coverage than through major changes in the active pharmaceutical ingredient or manufacturing process.
Downstream Market Opportunities
The principal downstream opportunity is the integration of Doxycycline Post-Exposure Prophylaxis Doxy-PEP into comprehensive sexual health management for populations with recurrent bacterial STI exposure. Sexual health clinics and HIV PrEP programs are particularly important because they already provide repeated testing, counseling, prescription management and follow-up. CDC guidance specifically positions Doxy-PEP within a broader sexual health approach that includes STI screening, vaccination and linkage with HIV prevention or care. As these service models expand, recurring prescriptions and standardized follow-up may improve treatment continuity and increase consumption visibility for suppliers.
Regional Insights
North America is currently the leading market for Doxycycline Post-Exposure Prophylaxis Doxy-PEP, reflecting earlier guideline development, established HIV PrEP infrastructure, stronger awareness among sexual health providers and relatively broad access to inexpensive generic doxycycline. The United States remains the principal commercial center, with Doxy-PEP already incorporated into formal CDC clinical guidance. Canada also represents a relevant market because of established generic doxycycline availability and developed sexual health services.
Europe is moving into a more structured adoption phase. The UK introduced national Doxy-PEP guidance in 2025, while ECDC issued EU and EEA public health considerations in January 2026. European expansion is expected to remain more selective because antimicrobial stewardship plays a prominent role in implementation. Australia and other developed Asia-Pacific markets have meaningful clinical potential, while broader Asia, Latin America and emerging markets remain earlier-stage opportunities. WHO’s July 2026 recommendation is expected to improve policy visibility in these regions, although implementation speed will depend on national STI programs, prescribing rules and access to sexual health services.
Competitive Landscape Analysis
The competitive landscape is fragmented and strongly shaped by the mature generic nature of doxycycline. Large multinational and regional generic manufacturers such as Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Sandoz Group, Viatris, Hikma Pharmaceuticals, Zydus Lifesciences, Lupin, Apotex, Amneal Pharmaceuticals, Macleods Pharmaceuticals, STADA Arzneimittel, Strides Pharma Science and Zhejiang Huahai Pharmaceutical participate alongside numerous mid-sized and regional manufacturers. Competition centers on manufacturing cost, regulatory coverage, finished-dosage capacity, continuity of supply and access to national pharmacy and healthcare channels rather than proprietary Doxy-PEP technology. Manufacturers with existing 100 mg or 200 mg oral doxycycline registrations are structurally advantaged because incremental Doxy-PEP demand can be absorbed through existing production systems without major capital investment. The market is therefore expected to remain highly price competitive, with regional availability and regulatory positioning determining commercial participation more than product differentiation.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Doxycycline Post-Exposure Prophylaxis Doxy-PEP market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd.
Sandoz Group AG
Viatris Inc.
Hikma Pharmaceuticals PLC
Zydus Lifesciences Limited
Lupin Limited
Apotex Inc.
Amneal Pharmaceuticals, Inc.
Macleods Pharmaceuticals Limited
STADA Arzneimittel AG
Strides Pharma Science Limited
Zhejiang Huahai Pharmaceutical Co., Ltd.
Ajanta Pharma Limited
Micro Labs Limited
Alembic Pharmaceuticals Limited
USV Private Limited
Mayne Pharma Group Limited
Laboratorios Normon, S.A.
Pierre Fabre S.A.
Laboratorio Reig Jofre, S.A.
Shanghai Pharmaceuticals Holding Co., Ltd.
Zhejiang Yongtai Pharmaceutical Co., Ltd.
TC Pharmaceuticals Jiangsu Co., Ltd.
Kaifeng Pharmaceutical Group Co., Ltd.
Teyi Pharmaceutical Group Co., Ltd.
Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd.
Guangzhou Pui’s Pharmaceutical Factory Ltd.
Hunan Xiangya Pharmaceutical Co., Ltd.
Shaanxi Xi Yue Pharmaceutical Co., Ltd.
Pharmaniaga Manufacturing Berhad
Duopharma Manufacturing Bangi Sdn. Bhd.
Hovid Berhad
Y.S.P. Industries M Sdn. Bhd.
Yung Shin Pharmaceutical Industrial Co., Ltd.
Dynapharm M Sdn. Bhd.
Beacons Pharmaceuticals Pte. Ltd.
Bangkok Lab and Cosmetic Public Company Limited
Shinil Pharmaceutical Co., Ltd.
Scheele Laboratories Phils., Inc.
Laboratorios Llorens, S.L.
Square Pharmaceuticals PLC
Incepta Pharmaceuticals Ltd.
Chartwell Pharmaceuticals, LLC
Segment by Type
Tablets
Capsules
Other
Segment by Release Profile
Conventional Release
Delayed Release
Other
Segment by Application
HIV PrEP-linked STI Prevention
HIV Care-linked STI Prevention
Sexual Health Clinic STI Prevention
Primary Care STI Prevention
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Doxycycline Post-Exposure Prophylaxis Doxy-PEP study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Doxycycline Post-Exposure Prophylaxis Doxy-PEP: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Tablets
1.2.3 Capsules
1.2.4 Other
1.3 Market Segmentation by Release Profile
1.3.1 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size by Release Profile, 2021 vs 2025 vs 2032
1.3.2 Conventional Release
1.3.3 Delayed Release
1.3.4 Other
1.4 Market Segmentation by Application
1.4.1 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size by Application, 2021 vs 2025 vs 2032
1.4.2 HIV PrEP-linked STI Prevention
1.4.3 HIV Care-linked STI Prevention
1.4.4 Sexual Health Clinic STI Prevention
1.4.5 Primary Care STI Prevention
1.4.6 Other
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue Estimates and Forecasts (2021-2032)
2.2 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Estimates and Forecasts (2021-2032)
2.4 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Tablets: Market Share by Key Manufacturers
3.5.2 Capsules: Market Share by Key Manufacturers
3.5.3 Other: Market Share by Key Manufacturers
3.6 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Performance by Type
4.1.1 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Volume by Type (2021-2032)
4.1.2 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Performance by Release Profile
4.2.1 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Volume by Release Profile (2021-2032)
4.2.2 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Release Profile (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Release Profile (2021-2032)
4.3 Product Technology Differentiation
4.4 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.4.1 High-Growth Niches and Adoption Drivers
4.4.2 Profitability Hotspots and Cost Drivers
4.4.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Sun Pharmaceutical Industries Limited
11.1.1 Sun Pharmaceutical Industries Limited Corporation Information
11.1.2 Sun Pharmaceutical Industries Limited Business Overview
11.1.3 Sun Pharmaceutical Industries Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.1.4 Sun Pharmaceutical Industries Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Sun Pharmaceutical Industries Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Product in 2025
11.1.6 Sun Pharmaceutical Industries Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Application in 2025
11.1.7 Sun Pharmaceutical Industries Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Geographic Area in 2025
11.1.8 Sun Pharmaceutical Industries Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP SWOT Analysis
11.1.9 Sun Pharmaceutical Industries Limited Recent Developments
11.2 Teva Pharmaceutical Industries Ltd.
11.2.1 Teva Pharmaceutical Industries Ltd. Corporation Information
11.2.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.2.3 Teva Pharmaceutical Industries Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.2.4 Teva Pharmaceutical Industries Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 Teva Pharmaceutical Industries Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Product in 2025
11.2.6 Teva Pharmaceutical Industries Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Application in 2025
11.2.7 Teva Pharmaceutical Industries Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Geographic Area in 2025
11.2.8 Teva Pharmaceutical Industries Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP SWOT Analysis
11.2.9 Teva Pharmaceutical Industries Ltd. Recent Developments
11.3 Sandoz Group AG
11.3.1 Sandoz Group AG Corporation Information
11.3.2 Sandoz Group AG Business Overview
11.3.3 Sandoz Group AG Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.3.4 Sandoz Group AG Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Sandoz Group AG Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Product in 2025
11.3.6 Sandoz Group AG Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Application in 2025
11.3.7 Sandoz Group AG Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Geographic Area in 2025
11.3.8 Sandoz Group AG Doxycycline Post-Exposure Prophylaxis Doxy-PEP SWOT Analysis
11.3.9 Sandoz Group AG Recent Developments
11.4 Viatris Inc.
11.4.1 Viatris Inc. Corporation Information
11.4.2 Viatris Inc. Business Overview
11.4.3 Viatris Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.4.4 Viatris Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Viatris Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Product in 2025
11.4.6 Viatris Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Application in 2025
11.4.7 Viatris Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Geographic Area in 2025
11.4.8 Viatris Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP SWOT Analysis
11.4.9 Viatris Inc. Recent Developments
11.5 Hikma Pharmaceuticals PLC
11.5.1 Hikma Pharmaceuticals PLC Corporation Information
11.5.2 Hikma Pharmaceuticals PLC Business Overview
11.5.3 Hikma Pharmaceuticals PLC Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.5.4 Hikma Pharmaceuticals PLC Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 Hikma Pharmaceuticals PLC Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Product in 2025
11.5.6 Hikma Pharmaceuticals PLC Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Application in 2025
11.5.7 Hikma Pharmaceuticals PLC Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Geographic Area in 2025
11.5.8 Hikma Pharmaceuticals PLC Doxycycline Post-Exposure Prophylaxis Doxy-PEP SWOT Analysis
11.5.9 Hikma Pharmaceuticals PLC Recent Developments
11.6 Zydus Lifesciences Limited
11.6.1 Zydus Lifesciences Limited Corporation Information
11.6.2 Zydus Lifesciences Limited Business Overview
11.6.3 Zydus Lifesciences Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.6.4 Zydus Lifesciences Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 Zydus Lifesciences Limited Recent Developments
11.7 Lupin Limited
11.7.1 Lupin Limited Corporation Information
11.7.2 Lupin Limited Business Overview
11.7.3 Lupin Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.7.4 Lupin Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 Lupin Limited Recent Developments
11.8 Apotex Inc.
11.8.1 Apotex Inc. Corporation Information
11.8.2 Apotex Inc. Business Overview
11.8.3 Apotex Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.8.4 Apotex Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Apotex Inc. Recent Developments
11.9 Amneal Pharmaceuticals, Inc.
11.9.1 Amneal Pharmaceuticals, Inc. Corporation Information
11.9.2 Amneal Pharmaceuticals, Inc. Business Overview
11.9.3 Amneal Pharmaceuticals, Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.9.4 Amneal Pharmaceuticals, Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Amneal Pharmaceuticals, Inc. Recent Developments
11.10 Macleods Pharmaceuticals Limited
11.10.1 Macleods Pharmaceuticals Limited Corporation Information
11.10.2 Macleods Pharmaceuticals Limited Business Overview
11.10.3 Macleods Pharmaceuticals Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.10.4 Macleods Pharmaceuticals Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 Macleods Pharmaceuticals Limited Recent Developments
11.11 STADA Arzneimittel AG
11.11.1 STADA Arzneimittel AG Corporation Information
11.11.2 STADA Arzneimittel AG Business Overview
11.11.3 STADA Arzneimittel AG Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.11.4 STADA Arzneimittel AG Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 STADA Arzneimittel AG Recent Developments
11.12 Strides Pharma Science Limited
11.12.1 Strides Pharma Science Limited Corporation Information
11.12.2 Strides Pharma Science Limited Business Overview
11.12.3 Strides Pharma Science Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.12.4 Strides Pharma Science Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Strides Pharma Science Limited Recent Developments
11.13 Zhejiang Huahai Pharmaceutical Co., Ltd.
11.13.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Corporation Information
11.13.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
11.13.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.13.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
11.14 Ajanta Pharma Limited
11.14.1 Ajanta Pharma Limited Corporation Information
11.14.2 Ajanta Pharma Limited Business Overview
11.14.3 Ajanta Pharma Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.14.4 Ajanta Pharma Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 Ajanta Pharma Limited Recent Developments
11.15 Micro Labs Limited
11.15.1 Micro Labs Limited Corporation Information
11.15.2 Micro Labs Limited Business Overview
11.15.3 Micro Labs Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.15.4 Micro Labs Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 Micro Labs Limited Recent Developments
11.16 Alembic Pharmaceuticals Limited
11.16.1 Alembic Pharmaceuticals Limited Corporation Information
11.16.2 Alembic Pharmaceuticals Limited Business Overview
11.16.3 Alembic Pharmaceuticals Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.16.4 Alembic Pharmaceuticals Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 Alembic Pharmaceuticals Limited Recent Developments
11.17 USV Private Limited
11.17.1 USV Private Limited Corporation Information
11.17.2 USV Private Limited Business Overview
11.17.3 USV Private Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.17.4 USV Private Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 USV Private Limited Recent Developments
11.18 Mayne Pharma Group Limited
11.18.1 Mayne Pharma Group Limited Corporation Information
11.18.2 Mayne Pharma Group Limited Business Overview
11.18.3 Mayne Pharma Group Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.18.4 Mayne Pharma Group Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 Mayne Pharma Group Limited Recent Developments
11.19 Laboratorios Normon, S.A.
11.19.1 Laboratorios Normon, S.A. Corporation Information
11.19.2 Laboratorios Normon, S.A. Business Overview
11.19.3 Laboratorios Normon, S.A. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.19.4 Laboratorios Normon, S.A. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 Laboratorios Normon, S.A. Recent Developments
11.20 Pierre Fabre S.A.
11.20.1 Pierre Fabre S.A. Corporation Information
11.20.2 Pierre Fabre S.A. Business Overview
11.20.3 Pierre Fabre S.A. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.20.4 Pierre Fabre S.A. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.20.5 Pierre Fabre S.A. Recent Developments
11.21 Laboratorio Reig Jofre, S.A.
11.21.1 Laboratorio Reig Jofre, S.A. Corporation Information
11.21.2 Laboratorio Reig Jofre, S.A. Business Overview
11.21.3 Laboratorio Reig Jofre, S.A. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.21.4 Laboratorio Reig Jofre, S.A. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.21.5 Laboratorio Reig Jofre, S.A. Recent Developments
11.22 Shanghai Pharmaceuticals Holding Co., Ltd.
11.22.1 Shanghai Pharmaceuticals Holding Co., Ltd. Corporation Information
11.22.2 Shanghai Pharmaceuticals Holding Co., Ltd. Business Overview
11.22.3 Shanghai Pharmaceuticals Holding Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.22.4 Shanghai Pharmaceuticals Holding Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.22.5 Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments
11.23 Zhejiang Yongtai Pharmaceutical Co., Ltd.
11.23.1 Zhejiang Yongtai Pharmaceutical Co., Ltd. Corporation Information
11.23.2 Zhejiang Yongtai Pharmaceutical Co., Ltd. Business Overview
11.23.3 Zhejiang Yongtai Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.23.4 Zhejiang Yongtai Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.23.5 Zhejiang Yongtai Pharmaceutical Co., Ltd. Recent Developments
11.24 TC Pharmaceuticals Jiangsu Co., Ltd.
11.24.1 TC Pharmaceuticals Jiangsu Co., Ltd. Corporation Information
11.24.2 TC Pharmaceuticals Jiangsu Co., Ltd. Business Overview
11.24.3 TC Pharmaceuticals Jiangsu Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.24.4 TC Pharmaceuticals Jiangsu Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.24.5 TC Pharmaceuticals Jiangsu Co., Ltd. Recent Developments
11.25 Kaifeng Pharmaceutical Group Co., Ltd.
11.25.1 Kaifeng Pharmaceutical Group Co., Ltd. Corporation Information
11.25.2 Kaifeng Pharmaceutical Group Co., Ltd. Business Overview
11.25.3 Kaifeng Pharmaceutical Group Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.25.4 Kaifeng Pharmaceutical Group Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.25.5 Kaifeng Pharmaceutical Group Co., Ltd. Recent Developments
11.26 Teyi Pharmaceutical Group Co., Ltd.
11.26.1 Teyi Pharmaceutical Group Co., Ltd. Corporation Information
11.26.2 Teyi Pharmaceutical Group Co., Ltd. Business Overview
11.26.3 Teyi Pharmaceutical Group Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.26.4 Teyi Pharmaceutical Group Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.26.5 Teyi Pharmaceutical Group Co., Ltd. Recent Developments
11.27 Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd.
11.27.1 Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd. Corporation Information
11.27.2 Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd. Business Overview
11.27.3 Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.27.4 Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.27.5 Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd. Recent Developments
11.28 Guangzhou Pui’s Pharmaceutical Factory Ltd.
11.28.1 Guangzhou Pui’s Pharmaceutical Factory Ltd. Corporation Information
11.28.2 Guangzhou Pui’s Pharmaceutical Factory Ltd. Business Overview
11.28.3 Guangzhou Pui’s Pharmaceutical Factory Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.28.4 Guangzhou Pui’s Pharmaceutical Factory Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.28.5 Guangzhou Pui’s Pharmaceutical Factory Ltd. Recent Developments
11.29 Hunan Xiangya Pharmaceutical Co., Ltd.
11.29.1 Hunan Xiangya Pharmaceutical Co., Ltd. Corporation Information
11.29.2 Hunan Xiangya Pharmaceutical Co., Ltd. Business Overview
11.29.3 Hunan Xiangya Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.29.4 Hunan Xiangya Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.29.5 Hunan Xiangya Pharmaceutical Co., Ltd. Recent Developments
11.30 Shaanxi Xi Yue Pharmaceutical Co., Ltd.
11.30.1 Shaanxi Xi Yue Pharmaceutical Co., Ltd. Corporation Information
11.30.2 Shaanxi Xi Yue Pharmaceutical Co., Ltd. Business Overview
11.30.3 Shaanxi Xi Yue Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.30.4 Shaanxi Xi Yue Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.30.5 Shaanxi Xi Yue Pharmaceutical Co., Ltd. Recent Developments
11.31 Pharmaniaga Manufacturing Berhad
11.31.1 Pharmaniaga Manufacturing Berhad Corporation Information
11.31.2 Pharmaniaga Manufacturing Berhad Business Overview
11.31.3 Pharmaniaga Manufacturing Berhad Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.31.4 Pharmaniaga Manufacturing Berhad Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.31.5 Pharmaniaga Manufacturing Berhad Recent Developments
11.32 Duopharma Manufacturing Bangi Sdn. Bhd.
11.32.1 Duopharma Manufacturing Bangi Sdn. Bhd. Corporation Information
11.32.2 Duopharma Manufacturing Bangi Sdn. Bhd. Business Overview
11.32.3 Duopharma Manufacturing Bangi Sdn. Bhd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.32.4 Duopharma Manufacturing Bangi Sdn. Bhd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.32.5 Duopharma Manufacturing Bangi Sdn. Bhd. Recent Developments
11.33 Hovid Berhad
11.33.1 Hovid Berhad Corporation Information
11.33.2 Hovid Berhad Business Overview
11.33.3 Hovid Berhad Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.33.4 Hovid Berhad Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.33.5 Hovid Berhad Recent Developments
11.34 Y.S.P. Industries M Sdn. Bhd.
11.34.1 Y.S.P. Industries M Sdn. Bhd. Corporation Information
11.34.2 Y.S.P. Industries M Sdn. Bhd. Business Overview
11.34.3 Y.S.P. Industries M Sdn. Bhd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.34.4 Y.S.P. Industries M Sdn. Bhd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.34.5 Y.S.P. Industries M Sdn. Bhd. Recent Developments
11.35 Yung Shin Pharmaceutical Industrial Co., Ltd.
11.35.1 Yung Shin Pharmaceutical Industrial Co., Ltd. Corporation Information
11.35.2 Yung Shin Pharmaceutical Industrial Co., Ltd. Business Overview
11.35.3 Yung Shin Pharmaceutical Industrial Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.35.4 Yung Shin Pharmaceutical Industrial Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.35.5 Yung Shin Pharmaceutical Industrial Co., Ltd. Recent Developments
11.36 Dynapharm M Sdn. Bhd.
11.36.1 Dynapharm M Sdn. Bhd. Corporation Information
11.36.2 Dynapharm M Sdn. Bhd. Business Overview
11.36.3 Dynapharm M Sdn. Bhd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.36.4 Dynapharm M Sdn. Bhd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.36.5 Dynapharm M Sdn. Bhd. Recent Developments
11.37 Beacons Pharmaceuticals Pte. Ltd.
11.37.1 Beacons Pharmaceuticals Pte. Ltd. Corporation Information
11.37.2 Beacons Pharmaceuticals Pte. Ltd. Business Overview
11.37.3 Beacons Pharmaceuticals Pte. Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.37.4 Beacons Pharmaceuticals Pte. Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.37.5 Beacons Pharmaceuticals Pte. Ltd. Recent Developments
11.38 Bangkok Lab and Cosmetic Public Company Limited
11.38.1 Bangkok Lab and Cosmetic Public Company Limited Corporation Information
11.38.2 Bangkok Lab and Cosmetic Public Company Limited Business Overview
11.38.3 Bangkok Lab and Cosmetic Public Company Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.38.4 Bangkok Lab and Cosmetic Public Company Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.38.5 Bangkok Lab and Cosmetic Public Company Limited Recent Developments
11.39 Shinil Pharmaceutical Co., Ltd.
11.39.1 Shinil Pharmaceutical Co., Ltd. Corporation Information
11.39.2 Shinil Pharmaceutical Co., Ltd. Business Overview
11.39.3 Shinil Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.39.4 Shinil Pharmaceutical Co., Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.39.5 Shinil Pharmaceutical Co., Ltd. Recent Developments
11.40 Scheele Laboratories Phils., Inc.
11.40.1 Scheele Laboratories Phils., Inc. Corporation Information
11.40.2 Scheele Laboratories Phils., Inc. Business Overview
11.40.3 Scheele Laboratories Phils., Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Models, Descriptions and Specifications
11.40.4 Scheele Laboratories Phils., Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales, Price, Revenue and Gross Margin (2021-2026)
11.40.5 Scheele Laboratories Phils., Inc. Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Doxycycline Post-Exposure Prophylaxis Doxy-PEP Industry Chain
12.2 Doxycycline Post-Exposure Prophylaxis Doxy-PEP Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Doxycycline Post-Exposure Prophylaxis Doxy-PEP Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size Growth Rate by Release Profile, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Region (US$ Million), 2021-2026
Table 6. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Region (US$ Million), 2027-2032
Table 7. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Dose)
Table 8. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Region (K Dose), 2021-2026
Table 9. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Region (K Dose), 2027-2032
Table 10. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 11. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Manufacturers (K Dose), 2021-2026
Table 12. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Share by Manufacturers (2021-2026)
Table 13. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Manufacturers (US$ Million), 2021-2026
Table 14. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue-Based Market Share by Manufacturers (2021-2026)
Table 15. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 16. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue, 2025
Table 17. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 18. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Average Selling Price (ASP) by Manufacturers (US$/Dose), 2021-2026
Table 19. Key Manufacturers Doxycycline Post-Exposure Prophylaxis Doxy-PEP Manufacturing Base and Headquarters
Table 20. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Concentration Ratio (CR5)
Table 21. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 22. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 23. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Volume by Type (K Dose), 2021-2026
Table 24. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Volume by Type (K Dose), 2027-2032
Table 25. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Type (US$ Million), 2021-2026
Table 26. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Type (US$ Million), 2027-2032
Table 27. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Volume by Release Profile (K Dose), 2021-2026
Table 28. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Volume by Release Profile (K Dose), 2027-2032
Table 29. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Release Profile (US$ Million), 2021-2026
Table 30. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Release Profile (US$ Million), 2027-2032
Table 31. Technical Specifications by Key Product Type
Table 32. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Application (K Dose), 2021-2026
Table 33. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales by Application (K Dose), 2027-2032
Table 34. Doxycycline Post-Exposure Prophylaxis Doxy-PEP High-Growth Sectors Demand CAGR (2026-2032)
Table 35. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Application (US$ Million), 2021-2026
Table 36. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue by Application (US$ Million), 2027-2032
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Growth Accelerators and Market Barriers
Table 40. North America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 41. North America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 42. Europe Doxycycline Post-Exposure Prophylaxis Doxy-PEP Growth Accelerators and Market Barriers
Table 43. Europe Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 44. Europe Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 45. Asia-Pacific Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Asia-Pacific Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 47. Asia-Pacific Doxycycline Post-Exposure Prophylaxis Doxy-PEP Growth Accelerators and Market Barriers
Table 48. Southeast Asia Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Central and South America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Investment Opportunities and Key Challenges
Table 50. Central and South America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 51. Middle East and Africa Doxycycline Post-Exposure Prophylaxis Doxy-PEP Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 53. Sun Pharmaceutical Industries Limited Corporation Information
Table 54. Sun Pharmaceutical Industries Limited Description and Major Businesses
Table 55. Sun Pharmaceutical Industries Limited Product Models, Descriptions and Specifications
Table 56. Sun Pharmaceutical Industries Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 57. Sun Pharmaceutical Industries Limited Sales Value Proportion by Product in 2025
Table 58. Sun Pharmaceutical Industries Limited Sales Value Proportion by Application in 2025
Table 59. Sun Pharmaceutical Industries Limited Sales Value Proportion by Geographic Area in 2025
Table 60. Sun Pharmaceutical Industries Limited Doxycycline Post-Exposure Prophylaxis Doxy-PEP SWOT Analysis
Table 61. Sun Pharmaceutical Industries Limited Recent Developments
Table 62. Teva Pharmaceutical Industries Ltd. Corporation Information
Table 63. Teva Pharmaceutical Industries Ltd. Description and Major Businesses
Table 64. Teva Pharmaceutical Industries Ltd. Product Models, Descriptions and Specifications
Table 65. Teva Pharmaceutical Industries Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 66. Teva Pharmaceutical Industries Ltd. Sales Value Proportion by Product in 2025
Table 67. Teva Pharmaceutical Industries Ltd. Sales Value Proportion by Application in 2025
Table 68. Teva Pharmaceutical Industries Ltd. Sales Value Proportion by Geographic Area in 2025
Table 69. Teva Pharmaceutical Industries Ltd. Doxycycline Post-Exposure Prophylaxis Doxy-PEP SWOT Analysis
Table 70. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 71. Sandoz Group AG Corporation Information
Table 72. Sandoz Group AG Description and Major Businesses
Table 73. Sandoz Group AG Product Models, Descriptions and Specifications
Table 74. Sandoz Group AG Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 75. Sandoz Group AG Sales Value Proportion by Product in 2025
Table 76. Sandoz Group AG Sales Value Proportion by Application in 2025
Table 77. Sandoz Group AG Sales Value Proportion by Geographic Area in 2025
Table 78. Sandoz Group AG Doxycycline Post-Exposure Prophylaxis Doxy-PEP SWOT Analysis
Table 79. Sandoz Group AG Recent Developments
Table 80. Viatris Inc. Corporation Information
Table 81. Viatris Inc. Description and Major Businesses
Table 82. Viatris Inc. Product Models, Descriptions and Specifications
Table 83. Viatris Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 84. Viatris Inc. Sales Value Proportion by Product in 2025
Table 85. Viatris Inc. Sales Value Proportion by Application in 2025
Table 86. Viatris Inc. Sales Value Proportion by Geographic Area in 2025
Table 87. Viatris Inc. Doxycycline Post-Exposure Prophylaxis Doxy-PEP SWOT Analysis
Table 88. Viatris Inc. Recent Developments
Table 89. Hikma Pharmaceuticals PLC Corporation Information
Table 90. Hikma Pharmaceuticals PLC Description and Major Businesses
Table 91. Hikma Pharmaceuticals PLC Product Models, Descriptions and Specifications
Table 92. Hikma Pharmaceuticals PLC Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 93. Hikma Pharmaceuticals PLC Sales Value Proportion by Product in 2025
Table 94. Hikma Pharmaceuticals PLC Sales Value Proportion by Application in 2025
Table 95. Hikma Pharmaceuticals PLC Sales Value Proportion by Geographic Area in 2025
Table 96. Hikma Pharmaceuticals PLC Doxycycline Post-Exposure Prophylaxis Doxy-PEP SWOT Analysis
Table 97. Hikma Pharmaceuticals PLC Recent Developments
Table 98. Zydus Lifesciences Limited Corporation Information
Table 99. Zydus Lifesciences Limited Description and Major Businesses
Table 100. Zydus Lifesciences Limited Product Models, Descriptions and Specifications
Table 101. Zydus Lifesciences Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 102. Zydus Lifesciences Limited Recent Developments
Table 103. Lupin Limited Corporation Information
Table 104. Lupin Limited Description and Major Businesses
Table 105. Lupin Limited Product Models, Descriptions and Specifications
Table 106. Lupin Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. Lupin Limited Recent Developments
Table 108. Apotex Inc. Corporation Information
Table 109. Apotex Inc. Description and Major Businesses
Table 110. Apotex Inc. Product Models, Descriptions and Specifications
Table 111. Apotex Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. Apotex Inc. Recent Developments
Table 113. Amneal Pharmaceuticals, Inc. Corporation Information
Table 114. Amneal Pharmaceuticals, Inc. Description and Major Businesses
Table 115. Amneal Pharmaceuticals, Inc. Product Models, Descriptions and Specifications
Table 116. Amneal Pharmaceuticals, Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Amneal Pharmaceuticals, Inc. Recent Developments
Table 118. Macleods Pharmaceuticals Limited Corporation Information
Table 119. Macleods Pharmaceuticals Limited Description and Major Businesses
Table 120. Macleods Pharmaceuticals Limited Product Models, Descriptions and Specifications
Table 121. Macleods Pharmaceuticals Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Macleods Pharmaceuticals Limited Recent Developments
Table 123. STADA Arzneimittel AG Corporation Information
Table 124. STADA Arzneimittel AG Description and Major Businesses
Table 125. STADA Arzneimittel AG Product Models, Descriptions and Specifications
Table 126. STADA Arzneimittel AG Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. STADA Arzneimittel AG Recent Developments
Table 128. Strides Pharma Science Limited Corporation Information
Table 129. Strides Pharma Science Limited Description and Major Businesses
Table 130. Strides Pharma Science Limited Product Models, Descriptions and Specifications
Table 131. Strides Pharma Science Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Strides Pharma Science Limited Recent Developments
Table 133. Zhejiang Huahai Pharmaceutical Co., Ltd. Corporation Information
Table 134. Zhejiang Huahai Pharmaceutical Co., Ltd. Description and Major Businesses
Table 135. Zhejiang Huahai Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 136. Zhejiang Huahai Pharmaceutical Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
Table 138. Ajanta Pharma Limited Corporation Information
Table 139. Ajanta Pharma Limited Description and Major Businesses
Table 140. Ajanta Pharma Limited Product Models, Descriptions and Specifications
Table 141. Ajanta Pharma Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. Ajanta Pharma Limited Recent Developments
Table 143. Micro Labs Limited Corporation Information
Table 144. Micro Labs Limited Description and Major Businesses
Table 145. Micro Labs Limited Product Models, Descriptions and Specifications
Table 146. Micro Labs Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. Micro Labs Limited Recent Developments
Table 148. Alembic Pharmaceuticals Limited Corporation Information
Table 149. Alembic Pharmaceuticals Limited Description and Major Businesses
Table 150. Alembic Pharmaceuticals Limited Product Models, Descriptions and Specifications
Table 151. Alembic Pharmaceuticals Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 152. Alembic Pharmaceuticals Limited Recent Developments
Table 153. USV Private Limited Corporation Information
Table 154. USV Private Limited Description and Major Businesses
Table 155. USV Private Limited Product Models, Descriptions and Specifications
Table 156. USV Private Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 157. USV Private Limited Recent Developments
Table 158. Mayne Pharma Group Limited Corporation Information
Table 159. Mayne Pharma Group Limited Description and Major Businesses
Table 160. Mayne Pharma Group Limited Product Models, Descriptions and Specifications
Table 161. Mayne Pharma Group Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 162. Mayne Pharma Group Limited Recent Developments
Table 163. Laboratorios Normon, S.A. Corporation Information
Table 164. Laboratorios Normon, S.A. Description and Major Businesses
Table 165. Laboratorios Normon, S.A. Product Models, Descriptions and Specifications
Table 166. Laboratorios Normon, S.A. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 167. Laboratorios Normon, S.A. Recent Developments
Table 168. Pierre Fabre S.A. Corporation Information
Table 169. Pierre Fabre S.A. Description and Major Businesses
Table 170. Pierre Fabre S.A. Product Models, Descriptions and Specifications
Table 171. Pierre Fabre S.A. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 172. Pierre Fabre S.A. Recent Developments
Table 173. Laboratorio Reig Jofre, S.A. Corporation Information
Table 174. Laboratorio Reig Jofre, S.A. Description and Major Businesses
Table 175. Laboratorio Reig Jofre, S.A. Product Models, Descriptions and Specifications
Table 176. Laboratorio Reig Jofre, S.A. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 177. Laboratorio Reig Jofre, S.A. Recent Developments
Table 178. Shanghai Pharmaceuticals Holding Co., Ltd. Corporation Information
Table 179. Shanghai Pharmaceuticals Holding Co., Ltd. Description and Major Businesses
Table 180. Shanghai Pharmaceuticals Holding Co., Ltd. Product Models, Descriptions and Specifications
Table 181. Shanghai Pharmaceuticals Holding Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 182. Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments
Table 183. Zhejiang Yongtai Pharmaceutical Co., Ltd. Corporation Information
Table 184. Zhejiang Yongtai Pharmaceutical Co., Ltd. Description and Major Businesses
Table 185. Zhejiang Yongtai Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 186. Zhejiang Yongtai Pharmaceutical Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 187. Zhejiang Yongtai Pharmaceutical Co., Ltd. Recent Developments
Table 188. TC Pharmaceuticals Jiangsu Co., Ltd. Corporation Information
Table 189. TC Pharmaceuticals Jiangsu Co., Ltd. Description and Major Businesses
Table 190. TC Pharmaceuticals Jiangsu Co., Ltd. Product Models, Descriptions and Specifications
Table 191. TC Pharmaceuticals Jiangsu Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 192. TC Pharmaceuticals Jiangsu Co., Ltd. Recent Developments
Table 193. Kaifeng Pharmaceutical Group Co., Ltd. Corporation Information
Table 194. Kaifeng Pharmaceutical Group Co., Ltd. Description and Major Businesses
Table 195. Kaifeng Pharmaceutical Group Co., Ltd. Product Models, Descriptions and Specifications
Table 196. Kaifeng Pharmaceutical Group Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 197. Kaifeng Pharmaceutical Group Co., Ltd. Recent Developments
Table 198. Teyi Pharmaceutical Group Co., Ltd. Corporation Information
Table 199. Teyi Pharmaceutical Group Co., Ltd. Description and Major Businesses
Table 200. Teyi Pharmaceutical Group Co., Ltd. Product Models, Descriptions and Specifications
Table 201. Teyi Pharmaceutical Group Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 202. Teyi Pharmaceutical Group Co., Ltd. Recent Developments
Table 203. Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd. Corporation Information
Table 204. Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd. Description and Major Businesses
Table 205. Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 206. Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 207. Guangzhou Baiyunshan Huacheng Pharmaceutical Co., Ltd. Recent Developments
Table 208. Guangzhou Pui’s Pharmaceutical Factory Ltd. Corporation Information
Table 209. Guangzhou Pui’s Pharmaceutical Factory Ltd. Description and Major Businesses
Table 210. Guangzhou Pui’s Pharmaceutical Factory Ltd. Product Models, Descriptions and Specifications
Table 211. Guangzhou Pui’s Pharmaceutical Factory Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 212. Guangzhou Pui’s Pharmaceutical Factory Ltd. Recent Developments
Table 213. Hunan Xiangya Pharmaceutical Co., Ltd. Corporation Information
Table 214. Hunan Xiangya Pharmaceutical Co., Ltd. Description and Major Businesses
Table 215. Hunan Xiangya Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 216. Hunan Xiangya Pharmaceutical Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 217. Hunan Xiangya Pharmaceutical Co., Ltd. Recent Developments
Table 218. Shaanxi Xi Yue Pharmaceutical Co., Ltd. Corporation Information
Table 219. Shaanxi Xi Yue Pharmaceutical Co., Ltd. Description and Major Businesses
Table 220. Shaanxi Xi Yue Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 221. Shaanxi Xi Yue Pharmaceutical Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 222. Shaanxi Xi Yue Pharmaceutical Co., Ltd. Recent Developments
Table 223. Pharmaniaga Manufacturing Berhad Corporation Information
Table 224. Pharmaniaga Manufacturing Berhad Description and Major Businesses
Table 225. Pharmaniaga Manufacturing Berhad Product Models, Descriptions and Specifications
Table 226. Pharmaniaga Manufacturing Berhad Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 227. Pharmaniaga Manufacturing Berhad Recent Developments
Table 228. Duopharma Manufacturing Bangi Sdn. Bhd. Corporation Information
Table 229. Duopharma Manufacturing Bangi Sdn. Bhd. Description and Major Businesses
Table 230. Duopharma Manufacturing Bangi Sdn. Bhd. Product Models, Descriptions and Specifications
Table 231. Duopharma Manufacturing Bangi Sdn. Bhd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 232. Duopharma Manufacturing Bangi Sdn. Bhd. Recent Developments
Table 233. Hovid Berhad Corporation Information
Table 234. Hovid Berhad Description and Major Businesses
Table 235. Hovid Berhad Product Models, Descriptions and Specifications
Table 236. Hovid Berhad Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 237. Hovid Berhad Recent Developments
Table 238. Y.S.P. Industries M Sdn. Bhd. Corporation Information
Table 239. Y.S.P. Industries M Sdn. Bhd. Description and Major Businesses
Table 240. Y.S.P. Industries M Sdn. Bhd. Product Models, Descriptions and Specifications
Table 241. Y.S.P. Industries M Sdn. Bhd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 242. Y.S.P. Industries M Sdn. Bhd. Recent Developments
Table 243. Yung Shin Pharmaceutical Industrial Co., Ltd. Corporation Information
Table 244. Yung Shin Pharmaceutical Industrial Co., Ltd. Description and Major Businesses
Table 245. Yung Shin Pharmaceutical Industrial Co., Ltd. Product Models, Descriptions and Specifications
Table 246. Yung Shin Pharmaceutical Industrial Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 247. Yung Shin Pharmaceutical Industrial Co., Ltd. Recent Developments
Table 248. Dynapharm M Sdn. Bhd. Corporation Information
Table 249. Dynapharm M Sdn. Bhd. Description and Major Businesses
Table 250. Dynapharm M Sdn. Bhd. Product Models, Descriptions and Specifications
Table 251. Dynapharm M Sdn. Bhd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 252. Dynapharm M Sdn. Bhd. Recent Developments
Table 253. Beacons Pharmaceuticals Pte. Ltd. Corporation Information
Table 254. Beacons Pharmaceuticals Pte. Ltd. Description and Major Businesses
Table 255. Beacons Pharmaceuticals Pte. Ltd. Product Models, Descriptions and Specifications
Table 256. Beacons Pharmaceuticals Pte. Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 257. Beacons Pharmaceuticals Pte. Ltd. Recent Developments
Table 258. Bangkok Lab and Cosmetic Public Company Limited Corporation Information
Table 259. Bangkok Lab and Cosmetic Public Company Limited Description and Major Businesses
Table 260. Bangkok Lab and Cosmetic Public Company Limited Product Models, Descriptions and Specifications
Table 261. Bangkok Lab and Cosmetic Public Company Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 262. Bangkok Lab and Cosmetic Public Company Limited Recent Developments
Table 263. Shinil Pharmaceutical Co., Ltd. Corporation Information
Table 264. Shinil Pharmaceutical Co., Ltd. Description and Major Businesses
Table 265. Shinil Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 266. Shinil Pharmaceutical Co., Ltd. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 267. Shinil Pharmaceutical Co., Ltd. Recent Developments
Table 268. Scheele Laboratories Phils., Inc. Corporation Information
Table 269. Scheele Laboratories Phils., Inc. Description and Major Businesses
Table 270. Scheele Laboratories Phils., Inc. Product Models, Descriptions and Specifications
Table 271. Scheele Laboratories Phils., Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 272. Scheele Laboratories Phils., Inc. Recent Developments
Table 273. Key Raw Materials Distribution
Table 274. Raw Materials Key Suppliers
Table 275. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 276. Milestones in Production Technology Evolution
Table 277. Distributors List
Table 278. Market Trends and Market Evolution
Table 279. Market Drivers and Opportunities
Table 280. Market Challenges, Risks, and Restraints
Table 281. Research Programs/Design for This Report
Table 282. Key Data Information from Secondary Sources
Table 283. Key Data Information from Primary Sources

List of Figures
Figure 1. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Product Picture
Figure 2. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Tablets Product Picture
Figure 4. Capsules Product Picture
Figure 5. Other Product Picture
Figure 6. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size Growth Rate by Release Profile, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Conventional Release Product Picture
Figure 8. Delayed Release Product Picture
Figure 9. Other Product Picture
Figure 10. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. HIV PrEP-linked STI Prevention
Figure 12. HIV Care-linked STI Prevention
Figure 13. Sexual Health Clinic STI Prevention
Figure 14. Primary Care STI Prevention
Figure 15. Other
Figure 16. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Report Years Considered
Figure 17. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue (US$ Million), 2021-2032
Figure 19. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 20. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue-Based Market Share by Region (2021-2032)
Figure 21. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales (K Dose), 2021-2032
Figure 22. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Dose)
Figure 23. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Market Share by Region (2021-2032)
Figure 24. Top 5 and Top 10 Manufacturers Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Volume Market Share in 2025
Figure 25. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue-Based Market Share Ranking (2025)
Figure 26. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 27. Tablets Revenue-Based Market Share by Manufacturer in 2025
Figure 28. Capsules Revenue-Based Market Share by Manufacturer in 2025
Figure 29. Other Revenue-Based Market Share by Manufacturer in 2025
Figure 30. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Volume-Based Market Share by Type (2021-2032)
Figure 31. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue-Based Market Share by Type (2021-2032)
Figure 32. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP ASP by Type (US$/Dose), 2021-2032
Figure 33. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Volume-Based Market Share by Release Profile (2021-2032)
Figure 34. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue-Based Market Share by Release Profile (2021-2032)
Figure 35. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP ASP by Release Profile (US$/Dose), 2021-2032
Figure 36. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue-Based Market Share (2021-2032)
Figure 37. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Market Share by Application (2021-2032)
Figure 38. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue-Based Market Share by Application (2021-2032)
Figure 39. Global Doxycycline Post-Exposure Prophylaxis Doxy-PEP ASP by Application (US$/Dose), 2021-2032
Figure 40. North America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales YoY (K Dose), 2021-2032
Figure 41. North America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue YoY (US$ Million), 2021-2032
Figure 42. North America Top 5 Manufacturers Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Revenue (US$ Million) in 2025
Figure 43. North America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Volume (K Dose) by Application (2021-2032)
Figure 44. North America Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Revenue (US$ Million) by Application (2021-2032)
Figure 45. US Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue (US$ Million), 2021-2032
Figure 46. Canada Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue (US$ Million), 2021-2032
Figure 47. Mexico Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue (US$ Million), 2021-2032
Figure 48. Europe Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales YoY (K Dose), 2021-2032
Figure 49. Europe Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue YoY (US$ Million), 2021-2032
Figure 50. Europe Top 5 Manufacturers Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Revenue (US$ Million) in 2025
Figure 51. Europe Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Volume (K Dose) by Application (2021-2032)
Figure 52. Europe Doxycycline Post-Exposure Prophylaxis Doxy-PEP Sales Revenue (US$ Million) by Application (2021-2032)
Figure 53. Germany Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue (US$ Million), 2021-2032
Figure 54. France Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue (US$ Million), 2021-2032
Figure 55. U.K. Doxycycline Post-Exposure Prophylaxis Doxy-PEP Revenue (US$ Million), 2021-2032